文献速递糖尿病肥胖与代谢综合征

血浆成纤维细胞生长因子21与非酒精性脂肪性肝炎严重程度相关

Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

横断面研究纳入187例BMI>25患者,评估血浆FGF21与肝活检证实的非酒精性脂肪性肝炎(NASH)严重程度的关系。血浆FGF21在NASH组(453±262 pg/mL)高于无NASH组(341±198 pg/mL)和无NAFLD组(325±289 pg/mL),且随坏死性炎症和纤维化严重程度增加,但与脂肪变性程度无关。FGF21与脂肪组织和骨骼肌胰岛素敏感性呈负相关。

要点

  • NASH患者血浆FGF21水平显著高于无NASH和无NAFLD者。
  • 血浆FGF21随坏死性炎症和纤维化严重程度增加,但与脂肪变性无关。
  • FGF21与脂肪组织和骨骼肌胰岛素敏感性呈负相关,与肝脏胰岛素敏感性无关。

核心结论

  • 血浆FGF21与NASH患者脂肪性肝炎严重程度相关,尤其是纤维化。
  • 测量FGF21可能有助于识别疾病进展风险最高的患者。

研究设计与样本

  • 横断面研究,在大学医院进行,纳入187例BMI>25的患者。
  • 所有患者接受高胰岛素-正葡萄糖钳夹评估组织特异性胰岛素抵抗,肝脏磁共振波谱定量肝内甘油三酯,空腹血浆FGF21检测;146例存在NAFLD者接受肝活检。

主要发现

  • NASH组(n=94)血浆FGF21为453±262 pg/mL,高于无NASH组(n=52;341±198 pg/mL,P=0.03)和无NAFLD组(n=41;325±289 pg/mL,P=0.02)。
  • 血浆FGF21与脂肪组织胰岛素敏感性呈负相关(r=-0.17,P=0.006),与骨骼肌胰岛素敏感性呈负相关(r=-0.23,P=0.007),与肝脏胰岛素敏感性无相关性。
  • 血浆FGF21随坏死性炎症严重程度增加(P=0.02),随纤维化严重程度增加更显著(P<0.001),但与脂肪变性加重无关(P=0.60)。

临床怎么用

  • 在肥胖和2型糖尿病患者中,血浆FGF21水平可能辅助识别NASH及纤维化风险较高的个体。

局限性

  • 横断面设计无法确定因果关系。
  • 样本来自单一大学医院,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The relationship between plasma fibroblast growth factor 21 (FGF21), insulin resistance, and steatohepatitis has not been systematically assessed. OBJECTIVE: To determine if higher plasma FGF21 is associated with worse steatohepatitis on liver biopsy in patients with nonalcoholic fatty liver disease (NAFLD). DESIGN AND SETTING: Cross-sectional study in a university hospital. PATIENTS INTERVENTIONS AND MAIN OUTCOME MEASURES: Patients with a body mass index >25 (n = 187) underwent: (i) euglycemic hyperinsulinemic clamp to assess tissue-specific insulin resistance (IR); (ii) liver magnetic resonance spectroscopy for intrahepatic triglyceride quantification, (iii) liver biopsy (if NAFLD present; n = 146); and (iv) fasting plasma FGF21 levels. METHODS AND RESULTS: Patients were divided into three groups: (i) No NAFLD (n = 41); (ii) No nonalcoholic steatohepatitis (NASH) (patients with isolated steatosis or borderline NASH; n = 52); and (iii) NASH (patients with definite NASH; n = 94). Groups were well-matched for age/sex, prevalence of type 2 diabetes mellitus, and hemoglobin A1c. During euglycemic hyperinsulinemic insulin clamp, insulin sensitivity in skeletal muscle and adipose tissue worsened from No NAFLD to NASH (both P < 0.001). Plasma FGF21 levels correlated inversely with insulin sensitivity in adipose tissue (r = -0.17, P = 0.006) and skeletal muscle (r = -0.23, P = 0.007), but not with liver insulin sensitivity. Plasma FGF21 was higher in patients with NASH (453 ± 262 pg/mL) when compared with the No NASH (341 ± 198 pg/mL, P = 0.03) or No NAFLD (325 ± 289 pg/mL, P = 0.02) groups. Plasma FGF21 increased with the severity of necroinflammation (P = 0.02), and most significantly with worse fibrosis (P < 0.001), but not with worsening steatosis (P = 0.60). CONCLUSIONS: Plasma FGF21 correlates with severity of steatohepatitis, in particular of fibrosis, in patients with NASH. Measurement of FGF21 may help identify patients at the highest risk of disease progression.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Barb D, Bril F, Kalavalapalli S, et al. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. J Clin Endocrinol Metab. 2019. PMID: 30848827. doi:10.1210/jc.2018-02414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。